摘要
背景:微RNA-19b(miR-19b)是测定少突胶质细胞增殖的关键。第10号染色体上的磷酸酶和张力蛋白同源物(PTEN)被认为是miR-19b的靶点,参与少突胶质细胞的分化和增殖。方法:采用髓鞘少突胶质糖蛋白(MOG35-55)诱导小鼠EAE。为逆转EAE,免疫后静脉注射人工合成的agomiR-19b。结果:在实验性自身免疫性脑脊髓炎(EAE)小鼠模型中,miR-19b的表达明显降低。这种下调与神经学评分有关,可以通过agomR-19b显着改善。结果表明,agomiR-19b可增加髓鞘碱性蛋白(MBP)和环核苷酸磷酸二酯酶(CNP)的表达,这两种酶是寡突胶质细胞的分子标记。此外,我们的研究还发现miR-19b可能影响EAE模型中PTEN的表达。结论:miR-19b的恢复可能通过影响PTEN在EAE发病机制中发挥治疗作用。
关键词: MIR-19b,实验性自身免疫性脑脊髓炎,少突胶质细胞,PTEN,ago-R-19b,MBP,CNP。
Current Molecular Medicine
Title:MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis
Volume: 18 Issue: 5
关键词: MIR-19b,实验性自身免疫性脑脊髓炎,少突胶质细胞,PTEN,ago-R-19b,MBP,CNP。
摘要: Background: MicroRNA-19b (miR-19b) is essential in determining oligodendroglia proliferation. Phosphatase and tensin homologue on chromosome 10 (PTEN) is considered the target of miR-19b and participates in oligodendrocyte differentiation and proliferation.
Methods: Murine EAE was induced by myelin oligodendrocyte glycoprotein (MOG35– 55). For EAE reversal, artificially synthesized agomiR-19b was intravenous injected after immunization.
Results: We found that the expression of miR-19b is significantly reduced in an experimental autoimmune encephalomyelitis (EAE) mouse model. This downregulation, which is associated with the neurological scores, can be dramatically ameliorated by agomiR-19b. Our results show that agomiR-19b increases the expression of myelin basic protein (MBP) and cyclic nucleotide phosphodiesterase (CNP), which are regularly utilized as molecular markers of oligodendrocytes. Furthermore, our study also revealed that miR-19b probably affects the expression of PTEN in the EAE model.
Conclusion: These results indicate that the restoration of miR-19b probably exerts its therapeutic effect by affecting PTEN in the pathogenesis of EAE.
Export Options
About this article
Cite this article as:
MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004123716
DOI https://dx.doi.org/10.2174/1566524018666181004123716 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders
Current Gene Therapy Inflammatory Signaling Networks as Targets for Pharmacological Intervention of Chronic Diseases
Current Signal Transduction Therapy Immune Responses to Gene Product of Inducible Promoters
Current Gene Therapy Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Immune-Glutamatergic Dysfunction as a Central Mechanism of the Autism Spectrum Disorders
Current Medicinal Chemistry Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Inflammation & Allergy - Drug Targets (Discontinued) Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Other Anti- Inflammatory Agents in the Treatment of Neurodegenerative Disease
Current Alzheimer Research Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders
Current Neuropharmacology Small Molecule and Biologic Modulators of the Immune Response to Hepatitis C Virus
Mini-Reviews in Medicinal Chemistry Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy